Summary & Overview
HCPCS J7521: Tacrolimus Granules, Oral Suspension, 0.1 mg
HCPCS Level II code J7521 denotes tacrolimus granules for preparation of an oral suspension at a strength of 0.1 mg. Tacrolimus is an immunosuppressant used primarily in transplant medicine and certain autoimmune conditions; the granule oral suspension formulation facilitates dosing for patients who cannot swallow capsules or require precise pediatric dosing. Nationally, this HCPCS code matters for pharmacy billing, specialty pharmacy management, and coverage determinations tied to transplant and chronic immunosuppression care.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication summarizes coverage and billing benchmarks, payer reimbursement considerations, clinical context for use of the oral suspension formulation, and how the code maps to pharmacy-dispensed outpatient services. Where payer-specific details are unavailable, the report notes data limitations.
Readers will learn what J7521 represents clinically and operationally, the typical sites of service where the product is dispensed, common billing modifiers used with HCPCS pharmaceuticals (listed separately), and the implications for pharmacy billing workflows and prior authorization processes. The summary provides a concise reference for coders, pharmacists, and revenue cycle stakeholders involved in managing outpatient immunosuppressant therapy billing.
Billing Code Overview
HCPCS Level II code J7521 represents tacrolimus, granules, oral suspension, 0.1 mg. This code covers the dispensation of tacrolimus formulated as granules for reconstitution into an oral suspension at a unit strength of 0.1 mg.
Service Type: Oral immunosuppressant medication administration (pharmacy-dispensed)
Typical Site of Service: Outpatient pharmacy or clinic-based pharmacy dispensing for ambulatory patients or patients preparing oral suspension for home administration
Clinical & Coding Specifications
Clinical Context
A pediatric or adult solid-organ transplant recipient requires ongoing immunosuppression management and is prescribed oral tacrolimus granules (J7521) to facilitate accurate dosing when standard capsules or tablets are not feasible. Typical scenarios include young children, patients with swallowing difficulties, or patients needing precise small-dose titration during the early post-transplant period or when converting from another formulation. The clinical workflow includes: an outpatient transplant clinic or specialty pharmacy dispensing the oral suspension granules; baseline and serial therapeutic drug monitoring (tacrolimus trough levels) ordered by the transplant physician or clinical pharmacist; dose adjustments made by the transplant team; and documentation of administration instructions and patient/caregiver education. Typical site of service is an outpatient specialty pharmacy, transplant clinic, or ambulatory infusion center where medications are dispensed and clinical follow-up occurs.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/No modifier | Use when no special circumstances apply to the administration or dispensing of J7521. |